trans-3,6-dibromo-3,4-dihydro-2H-1-benzopyran-4-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: trans-3,6-dibromo-3,4-dihydro-2H-1-benzopyran-4-ol
• 英文别名: (+/-)-trans-3,6-dibromochroman-4-ol；(3S,4S)-3,6-dibromo-3,4-dihydro-2H-chromen-4-ol
• 化学式: C₉H₈Br₂O₂
• 分子量: 307.969
• InChiKey: KRPCINGSDQZAME-CBAPKCEASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  trans-3,6-dibromo-3,4-dihydro-2H-1-benzopyran-4-ol 在 bis(η3-allyl-μ-chloropalladium(II)) 、 tri tert-butylphosphoniumtetrafluoroborate ammonium hydroxide 、 D-樟脑酸 、 碳酸氢钠 、 溶剂黄146 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 水 、 二甲基亚砜 、 异丙醇 、 甲苯 、 乙腈 为溶剂， 反应 27.67h， 生成 N-[(3R,4S)-3,4-二氢-3-[[(甲基氨基)羰基]氧基]-6-[4-(3-氧杂环丁基)-1-哌嗪基]-2H-1-苯并吡喃-4-基]-4-氟-苯甲酰胺
  参考文献：
  名称：

  Cathepsin S Inhibitor Compounds

  摘要：

  本发明提供了化合物的化学式(I)： 或其药学上可接受的盐。此外，本发明提供了一种包含化合物的药物组合物的制剂(I)或其药学上可接受的盐与药学上可接受的稀释剂或载体。本发明还提供了治疗腹主动脉瘤、斑块不稳定性、动脉粥样硬化或类风湿性关节炎、牛皮癣和红斑狼疮等自身免疫性疾病的方法，包括给予化合物的治疗有效量的化合物的化学式(I)或其药学上可接受的盐或包含化合物的药物组合物的制剂(I)或其药学上可接受的盐和药学上可接受的稀释剂或载体。

  公开号：

  US20120095020A1
• 作为产物：
  描述：

  4-溴苯基炔丙基醚 在 N-溴代丁二酰亚胺(NBS) 、 N,N-二乙基苯胺 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 13.0h， 生成 trans-3,6-dibromo-3,4-dihydro-2H-1-benzopyran-4-ol
  参考文献：
  名称：

  Cardioselective Antiischemic ATP-Sensitive Potassium Channel Openers. 2. Structure-Activity Studies on Benzopyranylcyanoguanidines; Modification of the Benzopyran Ring

  摘要：

  The ATP-sensitive potassium channel (K-ATP) openers are of considerable interest as myocardial protecting agents. However, there exists a narrow window of safety for the use of first-generation compounds as antiischemic agents due to their powerful peripheral vasodilating effects, which can result in underperfusion of the area already at risk. We have recently disclosed the discovery of benzopyranylcyanoguanidine type K-ATP openers (BMS-180448) which are more selective for the ischemic myocardium compared to the first-generation compounds. This publication deals with structure-activity relationships for the antiischemic activity of the lead compound 8. The presence of an electron-withdrawing group at C6, an sp(3) center at C4, and a gem-dimethyl group at C2 appears to be essential for antiischemic activity. Cyanoguanidine can be replaced with a urea moiety. The results reported here support the hypothesis that distinct structure-activity relationships exist for antiischemic and vaso:relaxant activities of compounds related to 8 and cromakalim. The trifluoromethyl analog 10 is 550-fold more selective in vitro for the ischemic myocardium compared to the first-generation agent cromakalim. The reasons for the selectivity of these compounds for the ischemic myocardium are not clear at the present time. They may be related to the existence of receptor subtypes in smooth muscle and the myocardium.

  DOI：

  10.1021/jm00011a016

文献信息

• US8227468B2
  申请人：——

  公开号：US8227468B2

  公开（公告）日：2012-07-24
• Cathepsin S Inhibitor Compounds
  申请人：DENG Gary G.

  公开号：US20120095020A1

  公开（公告）日：2012-04-19

  The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The present invention further provides methods for treating abdominal aortic aneurysm, plaque instability, atherosclerosis, or autoimmune disorders such as rheumatoid arthritis, psoriasis, and lupus comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

  本发明提供了化合物的化学式(I)： 或其药学上可接受的盐。此外，本发明提供了一种包含化合物的药物组合物的制剂(I)或其药学上可接受的盐与药学上可接受的稀释剂或载体。本发明还提供了治疗腹主动脉瘤、斑块不稳定性、动脉粥样硬化或类风湿性关节炎、牛皮癣和红斑狼疮等自身免疫性疾病的方法，包括给予化合物的治疗有效量的化合物的化学式(I)或其药学上可接受的盐或包含化合物的药物组合物的制剂(I)或其药学上可接受的盐和药学上可接受的稀释剂或载体。
• Cardioselective Antiischemic ATP-Sensitive Potassium Channel Openers. 2. Structure-Activity Studies on Benzopyranylcyanoguanidines; Modification of the Benzopyran Ring
  作者：Karnail S. Atwal、Gary J. Grover、Francis N. Ferrara、Syed Z. Ahmed、Paul G. Sleph、Steven Dzwonczyk、Diane E. Normandin

  DOI：10.1021/jm00011a016

  日期：1995.5

  The ATP-sensitive potassium channel (K-ATP) openers are of considerable interest as myocardial protecting agents. However, there exists a narrow window of safety for the use of first-generation compounds as antiischemic agents due to their powerful peripheral vasodilating effects, which can result in underperfusion of the area already at risk. We have recently disclosed the discovery of benzopyranylcyanoguanidine type K-ATP openers (BMS-180448) which are more selective for the ischemic myocardium compared to the first-generation compounds. This publication deals with structure-activity relationships for the antiischemic activity of the lead compound 8. The presence of an electron-withdrawing group at C6, an sp(3) center at C4, and a gem-dimethyl group at C2 appears to be essential for antiischemic activity. Cyanoguanidine can be replaced with a urea moiety. The results reported here support the hypothesis that distinct structure-activity relationships exist for antiischemic and vaso:relaxant activities of compounds related to 8 and cromakalim. The trifluoromethyl analog 10 is 550-fold more selective in vitro for the ischemic myocardium compared to the first-generation agent cromakalim. The reasons for the selectivity of these compounds for the ischemic myocardium are not clear at the present time. They may be related to the existence of receptor subtypes in smooth muscle and the myocardium.